Cargando…

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer

BACKGROUND: Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC). The molecular mechanism or targets mediating irinotecan resistance are still unclear. It is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makondi, Precious Takondwa, Chu, Chi-Ming, Wei, Po-Li, Chang, Yu-Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531462/ https://www.ncbi.nlm.nih.gov/pubmed/28749961 http://dx.doi.org/10.1371/journal.pone.0180616

Ejemplares similares

Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer
por: Makondi, Precious Takondwa, et al.
Publicado: (2018)

Development of novel predictive miRNA/target gene pathways for colorectal cancer distance metastasis to the liver using a bioinformatic approach
por: Makondi, Precious Takondwa, et al.
Publicado: (2019)

Identification of Moesin (MSN) as a Potential Therapeutic Target for Colorectal Cancer via the β-Catenin-RUNX2 Axis
por: Huang, Chien-Yu, et al.
Publicado: (2023)

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Bromelain inhibits the ability of colorectal cancer cells to proliferate via activation of ROS production and autophagy
por: Chang, Tung-Cheng, et al.
Publicado: (2019)

Cytotoxic properties of unfractionated and fractionated bromelain alone or in combination with chemotherapeutic agents in colorectal cancer cells
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Human α-defensin 6 (HD6) suppresses CRC proliferation and metastasis through abolished EGF/EGFR signaling pathway
por: Wei, Po-Li, et al.
Publicado: (2022)

Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy
por: Huang, Chien-Yu, et al.
Publicado: (2019)

2,3,5,4′-Tetrahydroxystilbene (TG1), a Novel Compound Derived from 2,3,5,4′-Tetrahydroxystilbene-2-O-β-D-glucoside (THSG), Inhibits Colorectal Cancer Progression by Inducing Ferroptosis, Apoptosis, and Autophagy
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

PCTAIRE Protein Kinase 1 (PCTK1) Suppresses Proliferation, Stemness, and Chemoresistance in Colorectal Cancer through the BMPR1B-Smad1/5/8 Signaling Pathway
por: Wei, Po-Li, et al.
Publicado: (2023)

Identification of Sestrin3 Involved in the In vitro Resistance of Colorectal Cancer Cells to Irinotecan
por: Choi, Seung Ho, et al.
Publicado: (2015)

Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer
por: Kryczka, Jakub, et al.
Publicado: (2022)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer
por: Ruihua, Huang, et al.
Publicado: (2016)

Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Alliot, C
Publicado: (2006)

Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC
por: Lee, Soohyun, et al.
Publicado: (2018)

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancer
por: Sun, Xinrong, et al.
Publicado: (2017)

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
por: Glimelius, B, et al.
Publicado: (2011)

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
por: Ozawa, Shogo, et al.
Publicado: (2021)

Reply: Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2006)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
por: Seymour, Matthew T, et al.
Publicado: (2013)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

β-lactoglobulin-irinotecan inclusion complex as a new targeted nanocarrier for colorectal cancer cells
por: Bijari, Nooshin, et al.
Publicado: (2019)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Alliot, C, et al.
Publicado: (2004)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis()()
por: Erdem, Zeynep N., et al.
Publicado: (2017)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
por: Yue, Bei, et al.
Publicado: (2021)

Reply: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2004)

Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer
por: Okunaka, Mashiro, et al.
Publicado: (2021)

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer
por: Zhu, Jinwei, et al.
Publicado: (2023)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis
por: Sun, Fangfang, et al.
Publicado: (2019)

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
por: Ichikawa, W, et al.
Publicado: (2015)

Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway
por: Huang, Yan-Feng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gvnk9q0s6vcd91omseim4sl1uh